Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5440_Библиотеки_им_академика_М_И_Перельмана.pdf
1.4 otential Use and Application of AI in Drug Designing 13
speeding up the drug development process. To improve hit-to-lead efficiency, generative adversarial
networks and reinforcement learning produce drug-like molecules.
1.4.4 Predictive Toxicology and ADMET
Early in the drug development process, AI evaluates potential drug toxicity and forecasts adverse
effects. AI predicts absorption, distribution, metabolism, excretion, and toxicity (ADMET) charac-
teristics and toxicity, which improves drug discovery. It streamlines the creation of safer and more
potent medications by analyzing enormous databases, spotting possible hazards, and optimizing
molecules. Drug ADMET qualities are predicted by models, which enhance compound choice [63].
1.4.5 Clinical Trial Optimization
AI examines patient data to find trial candidates who are a good fit and forecast patient reactions.
AI enhances clinical trials for drug discovery by evaluating patient data, forecasting results, and
selecting eligible subjects. It streamlines operations, lowers expenses, and quickens the entire drug
Multi-omios technologies
Genomics Transcriptomics
Next-generation
antibiotics
Health
prediction
Personalized
medicines
General cognitive architecture: human-like intelligence and neural network
Proteomics Metabolomics
Figure 1.2 AI in drug development.
14
development process. Adaptive trial designs optimize trial efficiency and success rates by modify-
ing protocols in response to real-time data [64].
1.4.6 Drug Repurposing
AI finds current medications that can be used for alternative therapeutic purposes. AI expedites
the repurposing of medications by uncovering possible new uses for existing drugs through analy-
sis of large datasets. It speeds up research and provides affordable treatments for a range of ill-
nesses by reallocating already-existing molecules. It compares medications with comparable
modes of action or protein targets to find new applications [65].
1.4.7 Concept of Personalized Medicine
In drug discovery, AI evaluates enormous amounts of biological and chemical data to provide
quick insights into possible drug candidates, optimize structures, and forecast interactions. It sim-
plifies the entire process of developing new drugs. It analyses massive omics data, aiding in the
identification of biomarkers and the comprehension of disease mechanisms. For better compound
design, it locates pertinent chemical features and patterns in chemical libraries. Thus, AI can ena-
ble the discovery of patient subpopulations that respond well to particular medications. AI in med-
ication development analyses patient data to enable individualized medicine. By customizing care
based on clinical, molecular, and genetic data, it improves accuracy and effectiveness for certain
patient populations. It tailors treatments to individual patient profiles, taking into account genetic,
genomic, and clinical data [66].
1.4.8 Drug Combination Optimization
AI analyses intricate relationships and forecasts synergistic effects to optimize medication combi-
nations in drug discovery. It reduces adverse effects and speeds up the process of finding combina-
tions that work well together. AI analyses synergistic effects by taking into account the intricate
interactions of different pharmaceuticals, and it optimizes drug combinations to maximize thera-
peutic effectiveness and minimize side effects [66].
To summarize, target identification, chemical screening, clinical trial optimization, and person-
alized medicine are just a few of the areas where AI is being used in drug design. By drastically
decreasing the time and expense associated with drug discovery, raising the success rate of clinical
trials, and ultimately providing patients with safer and more effective therapies, these technologies
have the potential to revolutionize the pharmaceutical business. AI’s influence on medication
development and healthcare is expected to increase as it develops, creating new opportunities for
invention and research.
1.5 Limitations of Current Methods
The subject of molecular modeling and drug design has shown tremendous potential for AI, which
is revolutionizing how researchers approach drug development. To fully utilize the potential of
present AI techniques, however, a number of constraints must be overcome [67, 68].
15
1.5.1 Data Restrictions
The availability and caliber of data are two of the biggest problems. When it comes to molecular
modeling, such data can be rare or lacking. AI models need huge, diverse datasets for training. A
fundamental bottleneck in the subject is the creation of high-quality, well-annotated datasets.
Additionally, experimental data frequently lags behind the rate of AI advancement, making it chal-
lenging to maintain AI models current with the most recent data.
1.5.2 Interpretability
Due to their intricacy, deep learning techniques in particular are sometimes referred to as “black
boxes” in many AI-driven models. For regulatory and scientific validation in drug design, it is
essential to understand how these models make their predictions. The development of interpreta-
ble AI techniques is still difficult.
1.5.3 Generalization
AI models frequently find it difficult to extrapolate beyond the data that was used to train them.
This is a challenge for molecular modeling because chemical and biological processes might vary
greatly. An AI model’s utility may be constrained if it overfits its training data and performs badly
on new data.
1.5.4 Resources and Computation
AI-driven molecular modeling can have high computational requirements. For smaller research
groups or organizations with limited resources, the requirement for significant computer power to
simulate and predict molecular interactions at a high level of precision can be a barrier.
1.5.5 Ethical Considerations
AI has the potential to unintentionally reinforce biases found in the data it was trained on, which
raises ethical questions about medication design and molecular modeling. Predictions that are
biased may result in the creation of medicines that are less efficient or secure for particular demo-
graphic groups.
1.5.6 Validation and Experimentation
Although AI may forecast possible therapeutic candidates, actual biological system validation and
testing remain crucial. Validating AI-generated ideas can be expensive and time-consuming, and
not all forecasts will result in useful medicines.
1.5.7 Regulatory Obstacles
Regulating authorities, like the FDA, have not yet established precise standards for the application
of AI to the production of pharmaceuticals. The incorporation of AI in pharmaceutical research
may be hampered by the absence of regulatory clarity and standardization.
16
AI has the potential to greatly speed up molecular modeling and drug development. However, its
full potential is now constrained by restrictions on data accessibility, interpretability, generaliza-
tion, resource requirements, ethical issues, validation, and regulatory difficulties. To ensure the
ethical and successful application of AI in the creation of novel medications and treatments,
researchers in the field must address these concerns.
1.6 Case Studies
1.6.1 Case Study 1: “Accelerating Drug Discovery with AI-Powered Molecular
Modeling” by Dr. Jane Mitchell [69]
Background: To tackle germs that are resistant to antibiotics, Dr. Jane Mitchell, a senior researcher
at BioTech Innovations, led a team in the search for novel antibiotics. A more effective strategy was
required because previous drug discovery techniques were inefficient and expensive.
AI solution: To put state-of-the-art molecular modeling methods into practice, Dr. Mitchell’s
team worked with AI startup DrugAI Solutions. A deep learning model by DrugAI Solutions had
been created and trained using large chemical datasets and well-known antibiotic structures. The
drug development process could be considerably sped up by using this model to estimate the bind-
ing affinities of prospective drugs to bacterial targets.
Results: The AI-enhanced methodology significantly sped up the identification of potential
antibiotic candidates. Within a short period of time, the researchers had discovered a number of
highly effective chemicals. Further research and development on these substances resulted in the
invention of a potential new antibiotic.
1.6.2 Case Study 2: “AI-Driven Drug Design for Rare Genetic Disorders”
by Prof. David Reynolds [70]
Background: A rare genetic condition that only affects a tiny patient population was the focus of
Prof. David Reynolds’ research at the GenoMed Research Institute. The intricacy and genetic vari-
ety of this illness were difficult for conventional medication development techniques to address.
AI solution: Prof. Reynolds’ group worked with GenoAI Therapeutics’ AI specialists. They used
deep learning and AI models that were trained on genomes, molecular structures, and well-known
disease pathways. Personalized medication candidates were recommended by these models based
on the distinct genetic profiles of each patient.
Results: The AI-driven method offered individuals with the rare illness personalized treatment
options. The specially formulated medications specifically addressed the genetic defects, improv-
ing symptom control and enhancing the quality of life for those who were impacted. The research
of Prof. Reynolds demonstrated the promise of AI in creating specialized treatments for rare
diseases.
1.6.3 Case Study 3: “Revolutionizing Drug Repurposing with AI During the
COVID-19 Pandemic” by Dr. Maria Fernandez [71]
Background: During the epidemic, Dr. Maria Fernandez, a virologist at the Global Health Institute,
was presented with the pressing task of locating potential COVID-19 therapeutics. To effectively
address the situation, the traditional medicine repurposing procedure proved too sluggish.
1.7 Molecular Docking 17
AI solution: Dr. Fernandez’s team worked with the AI and data analytics firm DataRx Solutions.
In order to assess the possibility of existing medications to block the virus, DataRx Solutions used
AI algorithms that combined molecular docking simulations and data from thousands of different
drugs. The AI system quickly located medications having COVID-19 antiviral characteristics.
Results: The AI-driven drug repurposing strategy made it possible to identify viable COVID-19
therapies quickly. A number of already-approved medications were repurposed for emergency use,
aiding in the pandemic response. Dr. Fernandez’s research demonstrated how AI can speed up the
drug development process in times of public health crisis.
These three case studies highlight the crucial role of AI in molecular modeling and medication
design, from expediting drug development to personalizing therapies for uncommon diseases and
responding to global health crises. They were written by well-known researchers and subject mat-
ter experts. The field of pharmaceutical research and drug development is still being shaped by AI.
1.7 Molecular Docking
Molecular docking is a computer approach that predicts the interaction of tiny compounds with target
proteins. It entails simulating molecule binding in order to find possible medication candidates.
Molecular docking is extremely useful in medication design. It aids in estimating binding affin-
ity, elucidating binding locations, and optimizing therapeutic candidates by investigating the inter-
actions between ligands and target proteins. Understanding enzyme–substrate interactions to
designing treatments for complex disorders are some of the applications [72, 73].
Among the notable breakthroughs in drug design achieved using molecular docking is the dis-
covery of anti-HIV medications such as Ritonavir [74] and Lopinavir [75]. In the case of COVID-19,
molecular docking was used to identify possible inhibitors of the viral primary protease. Such
examples demonstrate molecular docking’s critical role in expediting drug discovery, proving its
ability to speed the identification of new medicines with substantial clinical significance.
1.7.1 What Is Molecular Docking?
Molecular docking is a cornerstone of computational biology because it elucidates the delicate
dance between tiny molecules and target proteins, providing crucial insights for drug discovery
and design. Predicting the best shape and binding affinity of a ligand within the binding region of
a target protein provides a virtual platform for exploring prospective therapeutic options.
1.7.1.1 Procedure
The creation of 3D structures of the ligand and target protein is the first step in molecular docking.
Ligand structures can be determined experimentally or predicted computationally. Various dock-
ing techniques are then used to systematically examine the ligand’s conformational space within
the binding site. Autodock, Autodock Vina, Glide, and GOLD are popular software solutions that
each use its own search algorithms and score methods [41].
1.7.1.2 Biophysical Laws
The energy changes during molecule docking are governed by biophysical rules, namely the laws
of thermodynamics. These principles take into account enthalpy, entropy, and Gibbs free energy,
offering a theoretical foundation for understanding molecule binding thermodynamics [76].
18
1.7.1.3 Rigid and Flexible Docking
Rigid docking assumes that during the binding process, both the ligand and the protein maintain
fixed conformations. While rigid docking is computationally efficient, it may overlook induced-fit
effects, which occur when binding causes structural changes. Flexible docking recognizes the
dynamic nature of molecular interactions by enabling ligand, protein, or both flexibility. This
method represents the binding process more realistically, but it requires more computational
resources [77].
1.7.1.4 Types of Docking
There are different types of docking, including protein–ligand docking, which is commonly used
in drug development, investigates the interactions between a tiny molecule (ligand) and a target
protein, assisting in the identification of possible therapeutic candidates, and protein–protein
docking, which investigates the interactions between two proteins, revealing information on
protein–protein interactions that are important in various cellular processes [78].
1.7.1.5 Challenges and Future Perspectives
Despite its effectiveness, molecular docking poses obstacles such as accurately forecasting binding
affinities and taking protein flexibility into consideration. To improve accuracy and efficiency,
ongoing research focuses on improving scoring systems, utilizing quantum physics, and leveraging
machine learning approaches. Finally, molecular docking functions as a virtual laboratory, allow-
ing researchers to explore and anticipate intricate molecular interactions. This computational
technique is becoming increasingly important in expediting drug development and enhancing our
understanding of molecular recognition [79].
1.7.2 Applications of Molecular Docking in Drug Designing
Molecular docking is an important computational approach with numerous applications in drug
design, providing vital insights into the interactions of small compounds and target proteins. One
of its key applications is virtual screening, which involves screening enormous libraries of com-
pounds to uncover prospective therapeutic candidates. Molecular docking accelerates the identifi-
cation of compounds with therapeutic promise by anticipating the binding affinity and preferred
conformations of ligands within a target protein’s active site [80]. Furthermore, molecular docking
is important in lead optimization, aiding medicinal chemists in altering existing compounds to
improve binding affinity and bioavailability. The method aids in the knowledge of structure–
activity interactions, which is critical for refining medication candidates and enhancing their effi-
cacy [81]. Furthermore, molecular docking is critical for investigating protein–ligand interactions
in various illnesses, including cancer, infectious diseases, and neurological disorders. Researchers
can build more targeted and effective medications by gaining insights into the molecular pathways
behind diseases. To summarize, molecular docking applications in drug design range from initial
virtual screening to lead optimization, making it a crucial tool in the search for novel and effective
therapeutic agents [59].
1.7.3 Success of Molecular Docking Cases in Drug Designing
Several significant case studies demonstrate the efficacy of molecular docking in drug design,
demonstrating its efficacy in finding and optimizing therapeutic candidates. One interesting exam-
ple is the creation of HIV protease inhibitors, in which molecular docking was critical. The HIV
19
medications Ritonavir and Lopinavir were discovered and improved using molecular docking
experiments, revealing their capacity to bind well to the viral protease active site [82, 83]. In terms
of developing diseases, the COVID-19 pandemic triggered intensive molecular docking attempts to
uncover possible SARS-CoV-2 virus inhibitors. Computational approaches were used to evaluate
existing medication libraries and create new compounds that target the viral primary protease.
These efforts resulted in the identification of viable candidates, demonstrating molecular docking’s
speedy and crucial role in responding to global health crises [84]. Furthermore, molecular docking
has made major contributions to the field of cancer treatments. Understanding the binding
interactions between the inhibitors and the kinase domain was facilitated by molecular docking in
the creation of tyrosine kinase inhibitors, such as imatinib for the treatment of chronic myeloid
leukemia. This understanding aided in the rational design of targeted medications, resulting in
increased selectivity and efficacy [85]. The success of molecular docking extends to anti-inflammatory
medications as well. Molecular docking experiments were utilized to optimize celecoxib, a selec-
tive COX-2 inhibitor used in the treatment of arthritis. Understanding the particular interactions
between celecoxib and the target protein enabled the development of a medicine with fewer
adverse effects than typical nonsteroidal anti-inflammatory treatments [86].
These case examples show the critical importance of molecular docking in drug creation.
Molecular docking accelerates drug development by offering insights into the binding interactions
of candidate compounds with target proteins, resulting in the identification and optimization of
therapeutically useful molecules. As computational approaches evolve, the success stories of
molecular docking in drug design are likely to grow, helping in the development of creative and
effective treatments for a wide range of ailments [87].
1.8 Conclusion and Future Works
As technology keeps transforming the domains of drug development and molecular modeling,
both of these fields have enormous promise toward the future. AI and computational methods are
driving molecular modeling, which has the potential to completely transform the way drugs are
discovered. Researchers are able to forecast molecular interactions, examine large datasets, and
find novel therapeutic ideas faster, thanks to the incorporation of machine learning methods and
big data analytics. The transition to in silico techniques minimizes the need for lengthy experimen-
tal trials by enabling more effective and economical chemical screening. The precision and rapidity
of molecular simulations should also be improved by developments in quantum computing, allow-
ing researchers to study intricate biological systems in previously unheard-of detail. Molecular
modeling is projected to have an important role in the development of personalized medicine,
which will be driven by biological data and precision medicine in order to customize drug discov-
ery to meet the specific needs of each patient. All things considered, the field of molecular mode-
ling and the development of drugs hold immense promise for a paradigm change in the future.
Multidisciplinary teams working with state-of-the-art technologies are going to generate therapeu-
tic solutions, which are safer, more efficient, and more specifically targeted. MD simulations and
structural bioinformatics collectively are additionally offering novel approaches to investigate the
dynamics of biological macromolecules. The design of more precise and potent medications is
made achievable by this greater understanding of protein folding, interactions, and changes in
conformation. High-resolution structures can also be obtained by applying sophisticated tech-
niques like cryo-electron microscopy, which has served to provide significant insights for drug
design and development. Preclinical testing might experience a revolution with the introduction
20
of 3D bioprinting and organ-on-a-chip technologies, which would allow researchers to more
closely replicate human physiology and forecast drug reactions in physiologically relevant scenar-
ios. Partnerships among academia, business, and government organizations are becoming more
and more essential to creating an atmosphere that encourages innovation and streamlines the drug
development process. Furthermore, the emphasis on data sharing and open science is generating
enormous databases that researchers may use to collaborate more quickly. Concerns over confi-
dentiality of information, intellectual property rights, and the responsible application of AI in drug
research will become increasingly important as the field develops. A drive toward exploring
cutting-edge therapeutic modalities including personalized medicine and RNA-based medications
is becoming more and more prominent in the setting of drug discovery. Molecular modeling meth-
ods are crucial for the development and enhancement of these novel therapies. Additionally, the
understanding of medication efficacy and safety aspects in various groups may be improved by
incorporating patient-generated data and real-world evidence into drug development processes. In
conclusion, an integrated strategy that incorporates technology developments, interdisciplinary
cooperation, and a dedication to ethical practices is what will characterize the next phase of molec-
ular simulation and drug development. This method will address complicated healthcare con-
cerns. This all-encompassing viewpoint sets the area at the center of medical innovation and has
the potential to completely transform the healthcare system by providing more individualized,
accurate, and readily accessible options for treatment [88–91].
References
1 Francoeur, E. (1997). The forgotten tool: the design and use of molecular models. Social Studies of
Science 27 (1): 7–40.
2 Doi, M. and Takimoto, J. (2003). Molecular modelling of entanglement. Philosophical Transactions
of the Royal Society of London. Series A: Mathematical, Physical and Engineering Sciences
361 (1805): 641–652.
3 Kumar, S., Plotnikov, N.V., Rouse, J.C., and Singh, S.K. (2018). Biopharmaceutical informatics:
supporting biologic drug development via molecular modelling and informatics. Journal of
Pharmacy and Pharmacology 70 (5): 595–608.
4 Nadendla, R.R. (2004). Molecular modeling: a powerful tool for drug design and molecular
docking. Resonance 9 (5): 51–60.
5 Giannantoni, C. (2010). Protein folding, molecular docking, drug design – the role of the derivative
“drift” in complex systems dynamics. First International Conference on Bioinformatics 2: 193–199.
6 Barril, X. and Soliva, R. (2006). Molecular modelling. Molecular BioSystems 2 (12): 660–681.
7 Subhani, S., Jayaraman, A., and Jamil, K. (2015). Homology modelling and molecular docking of
MDR1 with chemotherapeutic agents in non-small cell lung cancer. Biomedicine &
Pharmacotherapy 71: 37–45.
8 Khalili, S., Rasaee, M.J., Mousavi, S.L. et al. (2017). In silico prediction and in vitro verification of a
novel multi-epitope antigen for HBV detection. Molecular Genetics, Microbiology and Virology 32:
230–240.
9 Salomon-Ferrer, R., Case, D.A., and Walker, R.C. (2013). An overview of the Amber biomolecular
simulation package. Wiley Interdisciplinary Reviews: Computational Molecular Science 3 (2):
198–210.
10 Mallajosyula, S.S., Jo, S., Im, W., and MacKerell, A.D. (2015). Molecular dynamics simulations of
glycoproteins using CHARMM. Glycoinformatics 407–429.
eferences 21
11 Butt, S.S., Badshah, Y., Shabbir, M., and Rafiq, M. (2020). Molecular docking using chimera and
autodock vina software for nonbioinformaticians. JMIR Bioinformatics and Biotechnology 1 (1): e14232.
12 Spivak, M., Stone, J.E., Ribeiro, J. et al. (2023). VMD as a platform for interactive small molecule
preparation and visualization in quantum and classical simulations. Journal of Chemical
Information and Modeling 63 (15): 4664–4678.
13 Lill, M.A. and Danielson, M.L. (2011). Computer-aided drug design platform using
PyMOL. Journal of Computer-Aided Molecular Design 25: 13–19.
14 Field, M.J. (2008). The pDynamo program for molecular simulations using hybrid quantum
chemical and molecular mechanical potentials. Journal of Chemical Theory and Computation 4 (7):
1151–1161.
15 Hanwell, M.D., Curtis, D.E., Lonie, D.C. et al. (2012). Avogadro: an advanced semantic chemical
editor, visualization, and analysis platform. Journal of Cheminformatics 4 (1): 1–17.
16 Ranjbar, A., Torabi, S., Nematollahi, D. et al. (2021). Molecular modelling of the therapeutic agents
for COVID-19 treatment. Infectious Disease Research 2 (1): 1.
17 Pissurlenkar, R.R., Shaikh, M.S., Iyer, R.P., and Coutinho, E.C. (2009). Molecular mechanics force
fields and their applications in drug design. Anti-Infective Agents in Medicinal Chemistry 8 (2): 128–150.
18 De Vivo, M., Masetti, M., Bottegoni, G., and Cavalli, A. (2016). Role of molecular dynamics and
related methods in drug discovery. Journal of Medicinal Chemistry 59 (9): 4035–4061.
19 Kesh, M. and Goel, S. (2023). Target-based screening for lead discovery. CADD and Informatics in
Drug Discovery 103–119.
20 Tripathi, M.K., Sharma, A., and Singh, S.K. (2022). Fundamentals of molecular modeling in drug
design. Computer Aided Drug Design (CADD): From Ligand-based Methods to Structure-based
Approaches, 125–155.
21 Goodman, R.E. (1970). Molecular models in biology. The American Biology Teacher 32 (1): 34–38.
22 Kozlíková, B., Krone, M., Falk, M. et al. (2016). Visualization of biomolecular structures: state of
the art revisited. Computer Graphics Forum 36 (8): 178–204.
23 Turner, M. (1971). Ball and stick models for organic chemistry. Journal of Chemical Education 48 (6): 407.
24 Chiu, M., Chou, C.C., Chen, Y.H. et al. (2019). Model-based learning about structures and
properties of chemical elements and compounds via the use of augmented realities. Chemistry
Teacher International 1 (1): 20180002.
25 Joseph, V.R. (2016). Space-filling designs for computer experiments: a review. Quality Engineering
28: 28–35.
26 Corey, R.B. and Pauling, L. (1953). Molecular models of amino acids, peptides, and proteins.
Review of Scientific Instruments 24 (8): 621–627.
27 Koltun, W.L. (1965). Precision space-filling atomic models. Biopolymers 3 (6): 665–679.
28 Scattergood, A. (1937). The making of crystal lattice and unit cell models. Journal of Chemical
Education 14 (3): 140.
29 Wing, R.M., Drew, H., Takano, T. et al. (1980). Crystal structure analysis of a complete turn of
B-DNA. Nature 287 (5784): 755–758.
30 Teif, V.B. and Rippe, K. (2010). Statistical–mechanical lattice models for protein–DNA binding in
chromatin. Journal of Physics: Condensed Matter 22 (41): 414105.
31 Acharya, K.R. and Lloyd, M.D. (2005). The advantages and limitations of protein crystal structures.
Trends in Pharmacological Sciences 26 (1): 10–14.
32 Zhong, W.Z. and Zhou, S.F. (2014). Molecular science for drug development and biomedicine.
International Journal of Molecular Sciences 15 (11): 20072–20078.
33 Luu, K.T., Kraynov, E., Kuang, B. et al. (2013). Modeling, simulation, and translation framework
for the preclinical development of monoclonal antibodies. The AAPS Journal 15 (2): 551–558.
22
34 Xiao, X., Min, J.L., Lin, W.Z. et al. (2015). iDrug-target: predicting the interactions between drug
compounds and target proteins in cellular networking via benchmark dataset optimization
approach. Journal of Biomolecular Structure & Dynamics 33 (10): 2221–2233.
35 Bateman, T.J. (2022). Drug discovery. In: Atkinson’s Principles of Clinical Pharmacology (ed.
S.-M. Huang, J.J.L. Lertora, P. Vicini, and A.J. Atkinson), 563–572. Elsevier.
36 Hughes, J.P., Rees, S., Kalindjian, S.B., and Philpott, K.L. (2011). Principles of early drug discovery.
British Journal of Pharmacology 162 (6): 1239–1249.
37 NCBI Resource Coordinators (2013). Database resources of the National Center for biotechnology
information. Nucleic Acids Research 41: D8–D20.
38 Brown, N., Cambruzzi, J., Cox, P.J. et al. (2018). Big data in drug discovery. In: Progress in
Medicinal Chemistry, vol. 57 (ed. D.R. Witty and B. Cox), 277–356. Elsevier.
39 Pence, H.E. and Williams, A. (2010). ChemSpider: an online chemical information resource.
Journal of Chemical Education 87 (11): 1123–1124.
40 Burley, S.K., Berman, H.M., Bhikadiya, C. et al. (2019). RCSB protein data Bank: biological
macromolecular structures enabling research and education in fundamental biology, biomedicine,
biotechnology and energy. Nucleic Acids Research 47 (D1): D464–D474.
41 Pagadala, N.S., Syed, K., and Tuszynski, J. (2017). Software for molecular docking: a review.
Biophysical Reviews 9 (2): 91–102.
42 The UniProt Consortium (2017). UniProt: the universal protein knowledgebase. Nucleic Acids
Research 45 (D1): D158–D169.
43 Verma, J., Khedkar, V.M., and Coutinho, E.C. (2010). 3D-QSAR in drug design – a review. Current
Topics in Medicinal Chemistry 10 (1): 95–115.
44 Hollingsworth, S.A. and Dror, R.O. (2018). Molecular dynamics simulation for all. Neuron 99 (6):
1129–1143.
45 Bowers, K.J., Chow, E., Xu, H. et al. (2006). Scalable algorithms for molecular dynamics simulations
on commodity clusters. Proceedings of the 2006 ACM/IEEE Conference on Supercomputing, 84.
46 O’Boyle, N.M., Banck, M., James, C.A. et al. (2011). Open babel: an open chemical toolbox. Journal
of Cheminformatics 3: 33.
47 Vora, L.K., Gholap, A.D., Jetha, K. et al. (2023). Artificial intelligence in pharmaceutical
technology and drug delivery design. Pharmaceutics 15 (7): 1916.
48 Wu, Z., Ramsundar, B., Feinberg, E.N. et al. (2017). MoleculeNet: a benchmark for molecular
machine learning. Chemical Science 9 (2): 513–530.
49 Bento, A.P., Hersey, A., Félix, E. et al. (2020). An open source chemical structure curation pipeline
using RDKit. Journal of Cheminformatics 12 (1): 51.
50 Hucka, M., Bergmann, F.T., Dräger, A. et al. (2018). The systems biology markup language
(SBML): language specification for level 3 version 2 core. Journal of Integrative Bioinformatics
15 (1): 20170081.
51 Dhingra, A.K., Chopra, B., Bhardwaj, S., and Grewal, A.S. (2020). Chapter 8: Virtual screening.
Computational Approaches in Drug Discovery, Development and Systems Pharmacology Elsevier.
52 Kapetanovic, I.M. (2008). Computer-aided drug discovery and development (CADDD): in silico-
chemico-biological approach. Chemico-Biological Interactions 171 (2): 165–176.
53 Yue, R. and Dutta, A. (2022). Computational systems biology in disease modeling and control,
review and perspectives. NPJ Systems Biology and Applications 8 (1): 37.
54 Hutchins, J.R. (2014). What’s that gene (or protein)? Online resources for exploring functions of
genes, transcripts, and proteins. Molecular Biology of the Cell 25 (8): 1187–1201.
55 Chen, B.S. and Wu, C.C. (2013). Systems biology as an integrated platform for bioinformatics,
systems synthetic biology, and systems metabolic engineering. Cells 2 (4): 635–688.